Home>>Analytical Standards>>Carbinoxamine-d6 (maleate)

Carbinoxamine-d6 (maleate)

Catalog No.GC49197

An internal standard for the quantification of carbinoxamine

Products are for research use only. Not for human use. We do not sell to patients.

Carbinoxamine-d6 (maleate) Chemical Structure

Cas No.: N/A

Size Price Stock Qty
1 mg
$187.00
In stock
5 mg
$840.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Carbinoxamine-d6 is intended for use as an internal standard for the quantification of carbinoxamine by GC- or LC-MS. Carbinoxamine is a competitive histamine H1 receptor antagonist (Ki = 2.3 nM) and first generation antihistamine.1 It is also an L-type calcium channel inhibitor (Ki = 1.08 nM).2 Carbinoxamine decreases negative inotropic activity in isolated guinea pig left atria and negative chronotropic activity in guinea pig spontaneously beating isolated right atria (EC50s = 250 and 480 nM, respectively). Formulations containing carbinoxamine have been used in the treatment of allergic rhinitis.

1.Tran, V.T., Chang, R.S.L., and Snyder, S.H.Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramineProc. Natl. Acad. Sci. U.S.A.75(12)6290-6294(1978) 2.Carosati, E., Budriesi, R., Ioan, P., et al.Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screeningJ. Med. Chem.51(18)5552-5565(2008)

Reviews

Review for Carbinoxamine-d6 (maleate)

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Carbinoxamine-d6 (maleate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.